A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)

NCT02998528 PHASE3 COMPLETED Results posted

The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC. This study has multiple primary endpoints.

Details

Lead sponsor	Bristol-Myers Squibb
Phase	PHASE3
Status	COMPLETED
Enrolment	505
Start date	Sat Mar 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non Small Cell Lung Cancer

Interventions

• Nivolumab
• Cisplatin
• Vinorelbine
• Gemcitabine
• Docetaxel
• Pemetrexed
• Carboplatin
• Paclitaxel
• Ipilimumab

Countries

France, Italy, Japan, Greece, Taiwan, Hungary, South Korea, Argentina, Canada, Romania, China, Spain, United States, Turkey (Türkiye), Brazil